Clinical trials
ARDS (Moderate or Severe) clinical trials
Below are recruiting ards (moderate or severe) clinical trials, each written for real people, not researchers. We’re tracking 1,473 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07158242RecruitingPhase 3
Study of a Medication for Children with Active Ulcerative Colitis
This study is testing an investigational medication for children with ulcerative colitis that has not responded well to standard treatments. It aims to see if the drug is safe and effective in reducing symptoms.
Aurora, ColoradoAges 2–17 - NCT07147049RecruitingPhase 2
Testing a new painkiller for moderate to severe pain after surgery
This trial tests a new tablet called HL-1186 for people with moderate to severe pain after certain surgeries. It aims to see if the drug is safe and works well for pain control.
Chengdu, SichuanAges 18–75 - NCT07098351Recruiting
A trial for a new itchy skin medicine for people on peritoneal dialysis
This trial tests if a medication called nalfurafine hydrochloride (taken as a tablet that melts in your mouth) can help reduce moderate to severe itching in people receiving peritoneal dialysis for chronic kidney disease.
Guangzhou, GuangdongAges 18–85 - NCT07101484Enrolling by invitation
Study of a new liquid dressing for moderate-severe uterine scarring
This trial tests a new liquid dressing made from human cells to see if it is safe and helps heal moderate to severe uterine scarring (intrauterine adhesions) in women who want to have children. Participants will receive the dressing during a hysteroscopic procedure.
Nanjing, JiangsuAges 20–40 - NCT06696417Recruiting
Testing vunakizumab for moderate to severe plaque psoriasis
This study tests a new drug called vunakizumab to see if it is safe and works well for people with moderate to severe plaque psoriasis. If you have not used biologic treatments before and meet other health requirements, you may be able to join.
Shenyang, LiaoningAges 18 years+ - NCT06937944RecruitingPhase 3
New Botox-like injection for frown lines
This study tests a new botulinum toxin injection (similar to Botox) to see how well it smooths moderate to severe frown lines between the eyebrows. The treatment is given as a single injection and may help soften those lines for several months.
Beijing, Beijing MunicipalityAges 18–65 - NCT06819891RecruitingPhase 3
Study of afimkibart for active Crohn's disease
This trial tests a new medicine called afimkibart for people with moderately to severely active Crohn's disease that has not responded well to other treatments. It aims to see if the medicine can safely reduce inflammation and improve symptoms.
Dothan, AlabamaAges 16–80 - NCT06766357RecruitingPhase 3
Cyclosporin gel for moderate to severe dry eye
This study tests a gel form of cyclosporine for people with moderate to severe dry eye that hasn't improved with other treatments. The gel is applied to the eye to help reduce inflammation and increase tear production.
Xiamen, FujianAges 18 years+ - NCT06723080RecruitingPhase 3
Oral VC005 for moderate to severe eczema
This study tests an investigational oral tablet (VC005) for adults with moderate to severe atopic dermatitis (eczema). It is for people whose eczema has not been controlled well enough with topical treatments.
Nanjing, JiangsuAges 18–75 - NCT06005103Recruiting
Testing a headband that sends brain pulses for depression
This study tests a new headband that sends gentle electrical pulses to the brain (T-PEMF) to lift depression. You might join if you have moderate to severe depression and don't have certain other conditions or implants.
Frederiksberg, Capital RegionAges 18–65 - NCT06456593RecruitingPhase 2
Obefazimod for moderate to severe Crohn's disease
This trial tests an experimental oral medication called obefazimod for people with moderate to severe Crohn's disease. It aims to see if the drug can reduce inflammation and improve symptoms when other treatments have not worked well.
Fairhope, AlabamaAges 18–75 - NCT06243315Enrolling by invitation
Long-term safety study of Ellansé-S filler for smile lines
This study tests the long-term safety of a dermal filler called Ellansé-S, which is made of small PCL microspheres. It is for people who want to treat moderate to deep lines from the nose to the corners of the mouth.
Guangzhou, GuangdongAges 18 years+ - NCT06158490Enrolling by invitationPhase 2
JYP0061 tablet for moderate to severe eczema
This trial tests a new tablet called JYP0061 for people with moderate to severe atopic dermatitis (eczema) that has lasted at least a year. It aims to see if the drug is safe and effective in reducing symptoms.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT05691218Recruiting
Early high-flow oxygen plus nebulized asthma medicine
This study tests whether giving fast, high-flow oxygen early—together with inhaled terbutaline via a vibrating mist—helps adults with moderate to severe asthma flare-ups in the emergency department. It aims to see if this approach improves breathing after initial treatment.
Poitiers, FranceAges 18 years+ - NCT05610566Recruiting
HighLife valve replacement for severe leaking mitral valve
This trial studies a new catheter-based valve replacement system for people with moderate to severe, or severe, mitral valve regurgitation (a leaky mitral valve). It aims to check whether the procedure is safe and can improve heart function compared with expected care.
Suzhou, JiangsuAges 18 years+ - NCT05655897Recruiting
Clips for leaky mitral valve in high-surgery-risk heart patients
This trial studies whether a device called GeminiOne can safely and effectively repair a leaky mitral valve using a catheter-based “clip” technique. It may help patients who have moderate-to-severe or severe valve leakage but are considered too high-risk for open surgery.
Suzhou, JiangsuAges 18 years+ - NCT07615010RecruitingPhase 2
agenT-797 Plus Standard Care for Severe Pneumonia With Respiratory Failure
This trial tests whether adding an experimental drug called agenT-797 to standard pneumonia treatment helps patients in the ICU who have severe pneumonia and serious difficulty breathing (acute hypoxemic respiratory failure). The drug is designed to help the immune system fight severe infection.
San Francisco, CaliforniaAges 18 years+ - NCT07464392Recruiting
Fecal transplant to prevent infections in severe pancreatitis
This trial tests whether a fecal microbiota transplant (FMT) can help prevent infections in people with moderately severe or severe acute pancreatitis. You may qualify if you are between 18 and 75, have had pancreatitis for 15 to 21 days, and already have a feeding tube in place.
Fuzhou, FujianAges 18–75 - NCT07309055RecruitingPhase 3
Study of SHR-1819 injection for teens with severe eczema
This trial tests an injectable medicine called SHR-1819 for teenagers aged 12 to 17 with severe atopic dermatitis (eczema) that has not responded well to creams or other treatments. The goal is to see if it can improve skin symptoms and reduce itching.
Shenyang, LiaoningAges 12–17 - NCT07226206RecruitingPhase 1/Phase 2
Gene therapy for adults with severe hemophilia A
This trial tests a new gene therapy called SPK-8011QQ for adults with severe or moderately severe hemophilia A. The goal is to see if a single infusion can help your body produce its own factor VIII, reducing or stopping the need for regular factor VIII injections.
Orange, CaliforniaAges 18 years+ - NCT07204639RecruitingPhase 2
Testing CBP-0276 for moderate to severe psoriasis
This trial tests a new medication, CBP-0276, to see if it improves psoriasis symptoms and quality of life. It is for people with moderate to severe plaque psoriasis who might need stronger treatment.
Mexico CityAges 18–70 - NCT07153809Recruiting
Fecal transplant for severe acute pancreatitis recovery
This trial tests whether a fecal transplant (transferring healthy gut bacteria from a donor) can help people with severe acute pancreatitis. It is for adults who are about 2 weeks past the onset of the disease and have started to recover but still have fluid buildup in the pancreas.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05717218Recruiting
Testing special breathing monitoring during VV-ECMO in ARDS
This trial checks whether a special “breathing sensor belt” that watches breathing in real time can be used safely in adults with severe lung failure (ARDS) who are on a machine called VV-ECMO. It may help the care team better monitor ventilation while you’re critically ill.
ParisAges 18 years+ - NCT07080905RecruitingPhase 3
Gene therapy study for teens with severe hemophilia B
This study tests a one-time gene therapy (CSL222) for teenage boys with severe or moderately severe hemophilia B. It aims to help their bodies produce the clotting factor they need, potentially reducing or eliminating the need for regular factor infusions.
Orange, CaliforniaAges 11.5 years–17.2 years
Hear when a new ARDS (Moderate or Severe) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for ards (moderate or severe)?
- Yes. Clin2 currently lists 1,473 recruiting ards (moderate or severe) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a ards (moderate or severe) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a ards (moderate or severe) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.